Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

893 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A case of invasive micropapillary carcinoma of the breast.
Ota D, Toyama T, Ichihara S, Mizutani M, Kamei K, Iwata H. Ota D, et al. Among authors: mizutani m. Breast Cancer. 2007;14(3):323-6. doi: 10.2325/jbcs.14.323. Breast Cancer. 2007. PMID: 17690513 Free article.
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.
Watanabe J, Ito Y, Ohsumi S, Mizutani M, Tashiro H, Sakurai K, Takahashi M, Saito T, Tsurutani J, Mukai H, Yoshinami T, Takao S, Yamamoto Y, Matsuoka T, Iwase H, Iwata H, Nakamura S, Saeki T. Watanabe J, et al. Among authors: mizutani m. Invest New Drugs. 2017 Dec;35(6):791-799. doi: 10.1007/s10637-017-0486-4. Epub 2017 Jun 29. Invest New Drugs. 2017. PMID: 28660549 Free PMC article.
[Effectiveness of breast ultrasound].
Mizutani M, Takada H, Ando Y, Fujita T, Iwata H. Mizutani M, et al. Nihon Rinsho. 2007 Jun 28;65 Suppl 6:298-303. Nihon Rinsho. 2007. PMID: 17682171 Review. Japanese. No abstract available.
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.
Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Miura S, Eguchi K, Shinkai T, Ando M, Watanabe T, Masuda N, Ohashi Y, Sano M, Noguchi S. Inoue K, et al. Among authors: mizutani m. Breast Cancer Res Treat. 2010 Jan;119(1):127-36. doi: 10.1007/s10549-009-0498-7. Epub 2009 Aug 19. Breast Cancer Res Treat. 2010. PMID: 19690954 Clinical Trial.
[Dose Reduction versus Dose-interval Prolongation in Eribulin Mesilate Monotherapy in Patients with Metastatic Breast Cancer: A Retrospective Comparative Study].
Sasaki T, Oshima Y, Mishima E, Ban A, Katsuragawa K, Nagamatsu H, Yoshioka Y, Tsukiyama I, Hisada T, Itakura Y, Mizutani M. Sasaki T, et al. Among authors: mizutani m. Yakugaku Zasshi. 2016 Jul 1;136(7):1023-9. doi: 10.1248/yakushi.15-00267. Epub 2016 Mar 31. Yakugaku Zasshi. 2016. PMID: 27040459 Free article. Japanese.
893 results